Bausch + Lomb (BLCO) said Wednesday it obtained European CE Mark approval for its LuxLife vision intraocular lens.
The LuxLife intraocular lens allow surgeons to treat the 79.5% of people with more than 0.5D of corneal astigmatism before cataract surgery, the company said.
The LuxLife intraocular lens will be commercially available in Europe in the coming weeks, Bausch + Lomb said.
The company's shares were rising 1% in recent trading.
Price: 11.03, Change: +0.13, Percent Change: +1.19
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.